Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers

Inclusion Criteria: * Males aged 18-55 yrs. (inclusive) * BMI: 19.0 to 30.0 kg/m2 (inclusive) * Weight: ≥ 60kg and ≤100kg * Subjects should be willing to use adequate contraception and not donate sperm from admission to clinical research center until 6 months post dosing. * All intermittent medications should have be stopped at least 14days prior to admission to the clinical research center. * All intermittent non topical medication must be stopped at least 30days prior to admission to the clinical research center. * Ability and willingness to abstain from ETOH 48hrs prior to admission to the clinical research center. * Medical history without significant findings per the PI * Resting supine systolic BP of ≤140mmHg and diastolic BP of ≤90mmHg * ECGs (via 12 lead) showing NCS findings per PI * All clinical laboratory tests of blood and urine, WNL and/or without clinically significant findings * Willing/able to sign ICF * Normal bowel habits * Negative medical history regarding fecal blood positivity * Normal and/or NCS spot protein/creatinine (PCR) ratio. Exclusion Criteria: * Previous participation in the current study * History of prior exposure to bevacizumab * Evidence of clinically significant findings * Cognitive and / or mentally impaired handicaps that would affect ability to make an informed consent and/or remain compliant to the requirements of this trial. * History of relevant drug and/or food related allergies. * History of or known hypersensitivity to bevacizumab or other recombinant human or humanized antibodies or inactive ingredients. * Tobacco product use w/I 1 yr. prior to drug administration. * History of ETOH and or drug abuse/addiction * Positive urine drug and ETOH screen for opiates, methadone, cocaine, amphetamines including XTC, cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants and ETOH. * Average intake of more than 24 units of ETOH / wk. (1 unit of ETOH equals \~250mL of beer, 100mL of wine or 35mL of spirits). * Consumption of any foods containing poppy seeds w/I 48 hrs. prior to screening and admission to the clinical research center * Positive screen for Hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies or anti-human immunodeficiency virus (HIV) 1 and 2 antibodies. * Participation in a drug study w/I 60days or 5 half-lives of the previous drug. * Participation in more than 3 other drug studies in the 10months prior to drug administration in the current protocol. * Donation or loss of more than 100mL of blood w/I 60days prior to drug administration. Donation or loss of more than 1.5liters of blood w/I the 10months prior to drug administration. * Strenuous exercise w/I 96 hrs. Prior to admission to the clinical research center. * Significant or acute illness w/I 5days prior to drug administration that may impact safety assessments per the judgement of the PI. * Unsuitable veins for infusion and/or venepuncture * Surgery including surgery with suturing via a dental procedure or would dehiscence w/I 28days of dosing. Any planned surgery or dental procedures during the study and for at least 30days after follow up. * Presence of a non-healing wound or fracture. * History of bleeding disorders * History of thromboembolic conditions * History of gastrointestinal perforations or any fistulae. * History of orthostatic hypotension, fainting spells, blackouts for any reasons. * History of hypertension * Medically significant dental disease or dental neglect with signs and or symptoms of local or systemic infection that would likely require a dental procedure during the course of study.